Different tocolytics appear equally safe long-term but we need both higher follow-up rates, and placebo-controlled trials in future.
Different tocolytics appear equally safe long-term but we need both higher follow-up rates, and placebo-controlled trials in future.
BJOG. 2020 Mar 29;:
Authors: Thornton JG
Abstract
Premature birth is not only the commonest cause of new-born babies dying, but also an important cause of long-term handicap. This is why the paper by van Winden et al. in this issue, reporting two-year outcomes for participants in their APOSTEL-3 trial, comparing atosiban with nifedipine tocolysis, is so important.
PMID: 32223008 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Thornton JG Tags: BJOG Source Type: research